SE0302760D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0302760D0
SE0302760D0 SE0302760A SE0302760A SE0302760D0 SE 0302760 D0 SE0302760 D0 SE 0302760D0 SE 0302760 A SE0302760 A SE 0302760A SE 0302760 A SE0302760 A SE 0302760A SE 0302760 D0 SE0302760 D0 SE 0302760D0
Authority
SE
Sweden
Prior art keywords
sub
sup
compounds
new compounds
formula
Prior art date
Application number
SE0302760A
Other languages
English (en)
Swedish (sv)
Inventor
Gary Johansson
Peter Brandt
Graeme J Dykes
Bjoern M Nilsson
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0302760A priority Critical patent/SE0302760D0/xx
Publication of SE0302760D0 publication Critical patent/SE0302760D0/xx
Priority to US10/536,603 priority patent/US20060148818A1/en
Priority to CA002540861A priority patent/CA2540861A1/fr
Priority to ZA200602756A priority patent/ZA200602756B/en
Priority to BRPI0415825-3A priority patent/BRPI0415825A/pt
Priority to PCT/SE2004/001508 priority patent/WO2005037834A1/fr
Priority to CNA2004800309147A priority patent/CN1871236A/zh
Priority to MXPA06004361A priority patent/MXPA06004361A/es
Priority to JP2006536482A priority patent/JP2007509140A/ja
Priority to AU2004281252A priority patent/AU2004281252A1/en
Priority to EA200600811A priority patent/EA200600811A1/ru
Priority to EP04793811A priority patent/EP1675856A1/fr
Priority to IL174593A priority patent/IL174593A0/en
Priority to NO20062239A priority patent/NO20062239L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Structural Engineering (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
SE0302760A 2003-10-20 2003-10-20 New compounds SE0302760D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE0302760A SE0302760D0 (sv) 2003-10-20 2003-10-20 New compounds
EP04793811A EP1675856A1 (fr) 2003-10-20 2004-10-20 Nouveaux derives tetrahydrospiro piperidine-2,7'-pyrrolo 3,2-b|pyridine et nouveaux derives indole utiles pour le traitement des troubles associes au recepteur 5-ht6
CNA2004800309147A CN1871236A (zh) 2003-10-20 2004-10-20 用于治疗5－HT6受体相关病症的新的四氢螺{哌啶－2,7′－吡咯并[3,2－b]吡啶}衍生物和新的吲哚衍生物
CA002540861A CA2540861A1 (fr) 2003-10-20 2004-10-20 Nouveaux derives tetrahydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine et nouveaux derives indole utiles pour le traitement des troubles associes au recepteur 5-ht6
ZA200602756A ZA200602756B (en) 2003-10-20 2004-10-20 Novel tetraydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor-related disorders
BRPI0415825-3A BRPI0415825A (pt) 2003-10-20 2004-10-20 novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6
PCT/SE2004/001508 WO2005037834A1 (fr) 2003-10-20 2004-10-20 Nouveaux derives tetrahydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine et nouveaux derives indole utiles pour le traitement des troubles associes au recepteur 5-ht6
US10/536,603 US20060148818A1 (en) 2003-10-20 2004-10-20 Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
MXPA06004361A MXPA06004361A (es) 2003-10-20 2004-10-20 Nuevos derivados de tetrahidroespiro{piperidin-2,7'-pirrolo[3,2-b]piridina} y nuevos derivados de indol utiles en el tratamiento de trastornos relacionados con el receptor de 5-ht6.
JP2006536482A JP2007509140A (ja) 2003-10-20 2004-10-20 ５−ＨＴ６受容体に関連する疾患の処置において有用な新規テトラヒドロスピロ｛ピペリジン−２，７’−ピロロ［３，２−ｂ］ピリジン誘導体および新規インドール誘導体
AU2004281252A AU2004281252A1 (en) 2003-10-20 2004-10-20 Novel tetraydrospiro{piperidine-2,7' -pyrrolo(3,2-b)pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor -related disorders
EA200600811A EA200600811A1 (ru) 2003-10-20 2004-10-20 НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
IL174593A IL174593A0 (en) 2003-10-20 2006-03-27 NOVEL TETRAHYDROSPIRO{PIPERIDINE-2,7'-PYRROLO[3,2-b]PYRIDINE} DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS
NO20062239A NO20062239L (no) 2003-10-20 2006-05-18 Nye tetrahydrospiro[piperidin-2,7'-pyrrolo[3,2-b]pyridinderivater og nye indolderivater nyttige i behandlingen av 5-HT6 reseptorrelaterte forstyrrelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302760A SE0302760D0 (sv) 2003-10-20 2003-10-20 New compounds
US52312603P 2003-11-18 2003-11-18

Publications (1)

Publication Number Publication Date
SE0302760D0 true SE0302760D0 (sv) 2003-10-20

Family

ID=34467906

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302760A SE0302760D0 (sv) 2003-10-20 2003-10-20 New compounds

Country Status (13)

Country Link
US (1) US20060148818A1 (fr)
EP (1) EP1675856A1 (fr)
JP (1) JP2007509140A (fr)
CN (1) CN1871236A (fr)
AU (1) AU2004281252A1 (fr)
BR (1) BRPI0415825A (fr)
CA (1) CA2540861A1 (fr)
EA (1) EA200600811A1 (fr)
IL (1) IL174593A0 (fr)
MX (1) MXPA06004361A (fr)
NO (1) NO20062239L (fr)
SE (1) SE0302760D0 (fr)
WO (1) WO2005037834A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
MY141862A (en) 2003-07-22 2010-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2008003703A1 (fr) * 2006-07-03 2008-01-10 Biovitrum Ab (Publ) Indoles utiles comme modulateurs de 5-ht6
US7960374B2 (en) 2006-10-30 2011-06-14 Proximagen Limited Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders
MX2009006757A (es) * 2007-01-08 2009-06-30 Suven Life Sciences Ltd Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
EP2120950B1 (fr) * 2007-03-21 2012-07-04 Glaxo Group Limited Utilisation de derives quinoleines pour le traitement de la douleur
US8507469B2 (en) * 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2009034581A1 (fr) * 2007-09-11 2009-03-19 Suven Life Sciences Limited Composés indolyle substitués et leur utilisation en tant que ligands de 5-ht6
EP2254564A1 (fr) 2007-12-12 2010-12-01 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
EP2638014B1 (fr) * 2010-11-08 2017-01-04 Lycera Corporation Tétrahydroquinolines et composés bicycliques associés n-sulphonylées pour l'inhibition de l'activité rorgamma et le traitement de maladies
WO2013169864A2 (fr) 2012-05-08 2013-11-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015095788A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie
WO2015095792A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Acides propioniques de carbamate benzoxazine et dérivés acides pour la modulation de l'activité de rorgamma et le traitement de maladie
EP3083588B1 (fr) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Composés hétérocycliques aromatiques et leur utilisation dans les produits pharmaceutiques
WO2015095795A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Tétrahydronaphtyridine, benzoxazine, aza-benzoxazine et composés bicycliques apparentés pour l'inhibition de l'activité de rorgamma et le traitement de maladie
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
EP3256450B1 (fr) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Composés pyrazole substitués utilisés en tant qu'inhibiteurs de ror-gamma-t et utilisations desdits composés
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
WO2017075185A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Acides benzoïques à substitution hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
CN109053534A (zh) * 2018-08-01 2018-12-21 苏州盖德精细材料有限公司 一种医药中间体4-硝基吲哚的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191141B1 (en) * 1999-08-12 2001-02-20 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
JP4184077B2 (ja) * 2000-11-02 2008-11-19 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
JP2004517072A (ja) * 2000-11-24 2004-06-10 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ障害の治療において有用な化合物
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2444095A1 (fr) * 2001-04-20 2002-10-31 Wyeth Derives d'heterocyclyloxy-, -thioxy- et aminobenzazol servant de ligands de 5-hydroxytryptamine-6
EA200301143A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
NZ529032A (en) * 2001-06-11 2007-04-27 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
ES2268113T3 (es) * 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
JP4390698B2 (ja) * 2002-06-05 2009-12-24 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための５−ｈｔ６レセプターモジュレーターとしての１−スルホニル−４−アミノアルコキシインドール誘導体
AU2003243091A1 (en) * 2002-06-20 2004-01-06 Biovitrum Ab (Publ) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Also Published As

Publication number Publication date
US20060148818A1 (en) 2006-07-06
NO20062239L (no) 2006-06-21
MXPA06004361A (es) 2006-06-27
AU2004281252A1 (en) 2005-04-28
EP1675856A1 (fr) 2006-07-05
CN1871236A (zh) 2006-11-29
JP2007509140A (ja) 2007-04-12
BRPI0415825A (pt) 2007-01-02
CA2540861A1 (fr) 2005-04-28
IL174593A0 (en) 2006-08-20
EA200600811A1 (ru) 2006-10-27
WO2005037834A1 (fr) 2005-04-28

Similar Documents

Publication Publication Date Title
SE0302760D0 (sv) New compounds
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
SE0201544D0 (sv) Novel compounds and thier use
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
AU2003246811A8 (en) Terphenyl derivatives, preparation thereof, compositions containing same
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NO20043367L (no) Oralt farmasoytisk preparat
EP2202222A3 (fr) Dérivés d&#39;indène, leur préparation et leur utilisation en tant que médicaments
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
WO2005060959A8 (fr) Derives de pyrazone et leur utilisation en tant qu&#39;antagonistes du recepteur de l&#39;orexine
NO20040881L (no) Orale antidiabetes midler.
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
SE0102055D0 (sv) New Compounds
SE0303480D0 (sv) Benzofuranes
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE308540T1 (de) Antithrombosemittel
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0311970A (pt) Novos compostos, seu uso e preparação
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
MXPA04006115A (es) Derivados de imidazoquinolina.